Sensorion SA (ENXTPA: ALSEN)
Health Care · Biotechnology · FR
€5.90
-10.74% today · -66.8% 1Y
Sensorion SA (ENXTPA: ALSEN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $76.66M and employs 66 people.
Over the last twelve months the share price has lost 66.8%, trading between 6.49 and 40.40.
Tweenvest scores Sensorion SA across four factors: quality 36/100, value 45/100. Its strongest factor is value.
ALSEN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $76.66M
- Revenue (TTM)
- $7.03M
- P/E
- —
- EPS
- -4.37
- Dividend yield
- —
- Beta (5Y)
- 0.55
- 52-week high
- €40.40
- 52-week low
- €6.49
- Avg volume (3M)
- —
- Shares outstanding
- 10.30M
- Employees
- 66
- Next earnings
- —
About Sensorion SA
Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing for individuals with Otoferlin deficiency, and USHER-T1-GT, targeting Usher syndrome Type 1. The company also advances SENS-401, a drug candidate for treating sudden sensorineural hearing loss. Sensorion's broader pipeline encompasses numerous experimental treatments aimed at restoring, treating, and preventing various conditions affecting the inner ear. They hold a collaboration agreement with Institut Pasteur concerning gene therapy for both pediatric and adult deafness. Additionally, Sensorion partners with Sonova Holding AG to integrate genetic analysis into the routine diagnosis of progressive adult hearing loss, combining advanced therapeutic approaches with traditional hearing aids. Founded in 2009, Sensorion SA operates primarily in France.
- ISIN
- FR0012596468
- Founded
- 2009
- Listed since
- Apr 21, 2015
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ABIONYX Pharma SAENXTPA: ABNX | $77.29M | €1.62 | -8.88% |
| PDS Biotechnology CorporationNasdaqCM: PDSB | $77.19M | $1.02 | -4.23% |
| OKYO Pharma LimitedNasdaqCM: OKYO | $77.14M | $1.39 | -5.44% |
| Covalon Technologies Ltd.TSXV: COV | $77.11M | CA$3.98 | 0.00% |
| CORESTEMCHEMON Inc.KOSDAQ: A166480 | $76.25M | ₩2,315.00 | +8.94% |
| MedPacto, Inc.KOSDAQ: A235980 | $75.59M | ₩2,970.00 | +5.88% |
| OS Therapies IncorporatedNYSEAM: OSTX | $74.72M | $1.62 | 0.00% |
| Gain Therapeutics, Inc.NasdaqGM: GANX | $74.63M | $1.62 | -5.56% |
Figures last refreshed Oct 4, 2026.